Table 1.

Consensus Statements on Platelet-rich Plasma

No.	Statement
1	An accepted nomenclature and classification system that encompasses autologous blood/plasma products and categorizes preparations in sufficient detail is required to facilitate comparison across studies. Efforts should be made to involve academics, clinicians, and industry representatives in this process to encourage widespread adoption of the system.
2	The influence of donor variance and processing and delivery factors on the composition of PRP must be established.
3	A validated assay of the efficacy of PRP should be established for each clinical application.
4	The relationship between PRP composition and efficacy should be established.
5	Minimum standards of reporting for all studies (preclinical and clinical) evaluating PRP must be established to facilitate communication and the interpretation and synthesis of scientific investigations. These standards must include measured characteristics of the PRP and factors relating to the donor, processing, and delivery of the PRP.
6	Specific formulations of PRP should be matched with specific pathologic indications.
7	Methods for establishing proof of safety and efficacy of PRP should be determined. This process may require evidence of phenotype stability or viability for each indication.

PRP = platelet-rich plasma